BioCentury

7:00 AM GMT, Oct 22, 2012
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Strategy

Race for rituximab

If all 11 planned rituximab biosimilars make it to the market, price will determine the winner. But Novartis AG's Sandoz Ltd. unit expects that fewer than half will get to the finish line, and that means price will be only part of the equation.

Rituximab's blockbuster sales and upcoming patent expirations have made it a popular target for biosimilars companies.

Rituxan/MabThera is a $6.5 billion drug for partners Biogen Idec Inc. and Roche's Genentech Inc. unit. The chimeric mAb against CD20 is approved in the U.S. and EU to treat non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL) and rheumatoid arthritis (RA). It is also approved in the EU to treat diffuse large B cell lymphoma (DLBCL).

The patents expire between 2015 and 2018 in the U.S. and next year in the rest of the world.

Dr. Reddy's Laboratories Ltd. launched its biosimilar version of rituximab as Reditux to treat NHL in India in 2007. The company would not comment on its plans to develop and

Read the full 1615 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.